Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension

American Journal of Respiratory and Critical Care Medicine

Volumn 186, Issue 9, 2012, Pages 897-908

  Savai, Rajkumar ^a   Pullamsetti, Soni S ^a,b   Kolbe, Julia ^b   Bieniek, Ewa ^b   Voswinckel, Robert ^a,b   Fink, Ludger ^c   Scheed, Axel ^d   Ritter, Christin ^b   Dahal, Bhola K ^b   Vater, Axel ^e   Klussmann, Sven ^e   Ghofrani, Hossein A ^b   Weissmann, Norbert ^b   Klepetko, Walter ^d   Banat, Gamal A ^b   Seeger, Werner ^a,b   Grimminger, Friedrich ^b   Schermuly, Ralph T ^a,b  

^a MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

^b Department of Internal Medicine ^*  (United States)

^c JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^d UNIVERSITY OF VIENNA   (Austria)

^e NOXXON PHARMA AG   (Germany)

Author keywords

Chemokines; Inflammation; Inflammatory cells; Pulmonary arterial hypertension; Pulmonary vascular remodeling

Indexed keywords

CD14 ANTIGEN; CD209 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; STROMAL CELL DERIVED FACTOR 1; TOLONIUM CHLORIDE; TRANSCRIPTION FACTOR FOXP3;

ADOLESCENT; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD3+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; HELPER CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; INFLAMMATORY INFILTRATE; LUNG BLOOD VESSEL; LUNG HEMODYNAMICS; LUNG PARENCHYMA; LUNG VASOCONSTRICTION; MACROPHAGE; MALE; MAST CELL; MONOCYTE; MONONUCLEAR CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; T LYMPHOCYTE; TISSUE SECTION;

ADULT; AIRWAY REMODELING; ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; HYPERTENSION, PULMONARY; IMMUNOHISTOCHEMISTRY; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; RATS; TISSUE CULTURE TECHNIQUES; YOUNG ADULT;

EID: 84868283518     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201202-0335OC     Document Type: Article

References (43)

1. Barst RJ. Pulmonary hypertension: past, present and future. Ann Thorac Med 2008;3:1-4.
2. Ghofrani HA, Barst RJ, Benza RL, Champion HC, Fagan KA, Grimminger F, Humbert M, Simonneau G, Stewart DJ, Ventura C, et al. Future perspectives for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:S108-S117.
3. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, et al . Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54:S43-S54.
4. Fartoukh M, Emilie D, Le Gall C, Monti G, Simonneau G, Humbert M. Chemokine macrophage inflammatory protein-1alpha MMA expression in lung biopsy specimens of primary pulmonary hypertension. Chest 1998; 114:50S-51S.
5. Humbert M, Monti G, Brenot F, Sitbon O, Portier A, Grangeot-Keros L, Duroux P, Galanaud P, Simonneau G, Emilie D. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 1995;151:1628-1631.
6. Sakamaki F, Kyotani S, Nagaya N, Sato N, Oya H, Satoh T, Nakanishi N. Increased plasma P-selectin and decreased thrombomodulin in pulmonary arterial hypertension were improved by continuous prostacyclin therapy. Circulation 2000;102:2720-2725.
7. Balabanian K, Foussat A, Dorfmuller P, Durand-Gasselin I, Capel F, Bouchet-Delbos L, Portier A, Marfaing-Koka A, Krzysiek R, Rimaniol AC, et al . CX(3)C chemokine fractalkine in pulmonary arterial hypertension. Am J Respir Crit Care Med 2002;165:1419-1425.
8. Dorfmuller P, Zarka V, Durand-Gasselin I, Monti G, Balabanian K, Garcia G, Capron F, Coulomb-Lhermine A, Marfaing-Koka A, Simonneau G, et al. Chemokine RANTES in severe pulmonary ar-terial hypertension. Am J Respir Crit Care Med 2002;165:534-539.
9. Sanchez O, Marcos E, Perros F, Fadel E, Tu L, Humbert M, Dartevelle P, Simonneau G, Adnot S, Eddahibi S. Role of endothelium-derived cc chemokine ligand 2 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2007;176:1041-1047.
10. Tuder RM, Groves B, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994;144:275-285.
11. Stacher E, Graham BB, Hunt JM, Gandjeva A, Groshong SD, McLaughlin VV, Jessup M, Grizzle WE, Aldred MA, Cool CD, et al. Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med 2012;186:261-272.
12. Perros F, Dorfmuller P, Souza R, Durand-Gasselin I, Mussot S, Mazmanian M, Herve P, Emilie D, Simonneau G, Humbert M. Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension. Eur Respir J 2007;29:462-468.
13. Perros F, Dorfmuller P, Montani D, Hammad H, Waelput W, Girerd B, Raymond N, Mercier O, Mussot S, Cohen-Kaminsky S, et al. Pul-monary lymphoid neogenesis in idiopathic pulmonary arterial hy-pertension. Am J Respir Crit Care Med 2012;185:311-321.
14. Ulrich S, Nicolls MR, Taraseviciene L, Speich R, Voelkel N. Increased regulatory and decreased CD8+ cytotoxic T cells in the blood of patients with idiopathic pulmonary arterial hypertension. Respiration 2008;75:272-280.
15. Darisipudi MN, Kulkarni OP, Sayyed SG, Ryu M, Migliorini A, Sagrinati C, Parente E, Vater A, Eulberg D, Klussmann S, et al. Dual blockade of the homeostatic chemokine CXCL12 and the proin-flammatory chemokine CCL2 has additive protective effects on dia-betic kidney disease. Am J Pathol 2011;179:116-124.
16. Savai R, Pullamsetti SS, Kolbe J, Bieniek E, Ghofrani HA, Weissmann N, Fink L, Klepetko W, Voswinckel R, Banat GA, et al. Involvement of immune/inflammatory cells to pathology of idiopathic pulmonary arterial hypertension [abstract]. Am J Respir Crit Care Med 2010;181: A4866.
17. Heath D, Yacoub M. Lung mast cells in plexogenic pulmonary arteriopathy. J Clin Pathol 1991;44:1003-1006.
18. Laumanns IP, Fink L, Wilhelm J, Wolff JC, Mitnacht-Kraus R, Graef-Hoechst S, Stein MM, Bohle RM, Klepetko W, Hoda MA, et al. The noncanonical WNT pathway is operative in idiopathic pulmonary arterial hypertension. Am J Respir Cell Mol Biol 2009;40:683-691.
19. Hassoun PM, Mouthon L, Barbera JA, Eddahibi S, Flores SC, Grimminger F, Jones PL, Maitland ML, Michelakis ED, Morrell NW, et al. Inflammation, growth factors, and pulmonary vascular remod-eling. J Am Coll Cardiol 2009;54:S10-S19.
20. Burke DL, Frid MG, Kunrath CL, Karoor V, Anwar A, Wagner BD, Strassheim D, Stenmark KR. Sustained hypoxia promotes the de-velopment of a pulmonary artery-specific chronic inflammatory mi-croenvironment. Am J Physiol Lung Cell Mol Physiol 2009;297:L238-L250.
21. Hall S, Brogan P, Haworth SG, Klein N. Contribution of inflammation to the pathology of idiopathic pulmonary arterial hypertension in chil-dren. Thorax 2009;64:778-783.
22. Stenmark KR, Davie NJ, Reeves JT, Frid MG. Hypoxia, leukocytes, and the pulmonary circulation. J Appl Physiol 2005;98:715-721.
23. Frid MG, Brunetti JA, Burke DL, Carpenter TC, Davie NJ, Reeves JT, Roedersheimer MT, van Rooijen N, Stenmark KR. Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage. Am J Pathol 2006;168:659-669.
24. Wilson HM, Barker RN, Erwig LP. Macrophages: promising targets for the treatment of atherosclerosis. Curr Vasc Pharmacol 2009;7:234-243.
25. Vergadi E, Chang MS, Lee C, Liang OD, Liu X, Fernandez-Gonzalez A, Mitsialis SA, Kourembanas S. Early macrophage recruitment and alternative activation are critical for the later development of hypoxia-inducedpulmonary hypertension. Circulation 2011;123:1986-1995.
26. Wu Q, Salomon B, Chen M, Wang Y, Hoffman LM, Bluestone JA, Fu YX. Reversal of spontaneous autoimmune insulitis in nonobese dia-betic mice by soluble lymphotoxin receptor. J Exp Med 2001;193: 1327-1332.
27. Austin ED, Rock MT, Mosse CA, Vnencak-Jones CL, Yoder SM, Robbins IM, Loyd JE, Meyrick BO. T lymphocyte subset abnor-malities in the blood and lung in pulmonary arterial hypertension. Respir Med 2010;104:454-462.
28. Levy M, Maurey C, Celermajer DS, Vouhe PR, Danel C, Bonnet D, Israel-Biet D. Impaired apoptosis of pulmonary endothelial cells is associated with intimal proliferation and irreversibility of pulmonary hypertension in congenital heart disease. J Am Coll Cardiol 2007;49: 803-810.
29. Mach F, Schonbeck U, Fabunmi RP, Murphy C, Atkinson E, Bonnefoy JY, Graber P, Libby P. T lymphocytes induce endo-thelial cell matrix metalloproteinase expression by a cd40l-dependent mechanism: implications for tubule formation. Am J Pathol 1999;154:229-238.
30. Freeman MR, Schneck FX, Gagnon ML, Corless C, Soker S, Niknejad K, Peoples GE, Klagsbrun M. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res 1995;55:4140-4145.
31. Bonnet S, Rochefort G, Sutendra G, Archer SL, Haromy A, Webster L, Hashimoto K, Bonnet SN, Michelakis ED. The nuclear factor of activated T cells in pulmonary arterial hypertension can be ther-apeutically targeted. Proc Natl Acad Sci USA 2007;104:11418-11423.
32. Daley E, Emson C, Guignabert C, de Waal Malefyt R, Louten J, Kurup VP, Hogaboam C, Taraseviciene-Stewart L, Voelkel NF, Rabinovitch M, et al. Pulmonary arterial remodeling induced by a Th2 immune response. J Exp Med 2008;205:361-372.
33. Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z, Shimizu J, Takahashi T, Nomura T. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006;212:8-27.
34. Yudoh K, Matsuno H, Osada R, Nakazawa F, Katayama R, Kimura T. Decreased cellular activity and replicative capacity of osteoblastic cells isolated from the periarticular bone of rheumatoid arthritis patients com-pared with osteoarthritis patients. Arthritis Rheum 2000;43:2178-2188.
35. Liu MF, Wang CR, Fung LL, Wu CR. Decreased CD4+CD25+ T cells in peripheral blood of patients with systemic lupus erythematosus. Scand J Immunol 2004;59:198-202.
36. Danese S, Rutella S. The Janus face of CD4+CD25+ regulatory T cells in cancer and autoimmunity. Curr Med Chem 2007;14:649-666.
37. Tamby MC, Humbert M, Guilpain P, Servettaz A, Dupin N, Christner JJ, Simonneau G, Fermanian J, Weill B, Guillevin L, et al. Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension. Eur Respir J 2006;28:799-807.
38. Nicolls MR, Taraseviciene-Stewart L, Rai PR, Badesch DB, Voelkel NF. Autoimmunity and pulmonary hypertension: a perspective. Eur Respir J 2005;26:1110-1118.
39. Bennaceur K, Popa I, Portoukalian J, Berthier-Vergnes O, Peguet-Navarro J. Melanoma-derived gangliosides impair migratory and antigen-presenting function of human epidermal Langerhans cells and induce their apoptosis. Int Immunol 2006;18:879-886.
40. Young KC, Torres E, Hatzistergos KE, Hehre D, Suguihara C, Hare JM. Inhibition of the SDF-1/CXCR4 axis attenuates neonatal hypoxia-induced pulmonary hypertension. Circ Res 2009;104:1293-1301.
41. Yu L, Hales CA. Effect of chemokine receptor CXCR4 on hypoxia-induced pulmonary hypertension and vascular remodeling in rats. Respir Res 2011;12:21.
42. Gambaryan N, Perros F, Montani D, Cohen-Kaminsky S, Mazmanian M, Renaud JF, Simonneau G, Lombet A, Humbert M. Targeting of c-kit+ haematopoietic progenitor cells prevents hypoxic pulmonary hypertension. Eur Respir J 2011;37:1392-1399.
43. Duda DG, Kozin SV, Kirkpatrick ND, Xu L, Fukumura D, Jain RK. CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin Cancer Res 2011;17:2074-2080.